Loading...
XWAR
BCX
Market cap138mUSD
Jun 02, Last price  
104.40PLN
1D
0.58%
1Q
1.56%
IPO
198.29%
Name

Bioceltix SA

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
3.58%
Rev. gr., 5y
%
Revenues
0k
01,50010,800000
Net income
-14m
L+53.42%
-775,690-1,596,337-2,348,754-4,397,615-8,921,382-13,687,545
CFO
-15m
L+86.53%
-1,786,672-1,669,645-1,511,961-4,040,510-7,906,198-14,747,690

Profile

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
IPO date
Nov 08, 2021
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
14,307
9,589
Unusual Expense (Income)
NOPBT
(14,307)
(9,589)
NOPBT Margin
Operating Taxes
(46)
Tax Rate
NOPAT
(14,307)
(9,543)
Net income
(13,688)
53.42%
(8,921)
102.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,669
6,529
BB yield
-5.86%
-5.04%
Debt
Debt current
99
116
Long-term debt
175
356
Deferred revenue
2
Other long-term liabilities
38
Net debt
(9,037)
(3,648)
Cash flow
Cash from operating activities
(14,748)
(7,906)
CAPEX
(458)
(352)
Cash from investing activities
(458)
(352)
Cash from financing activities
20,396
6,323
FCF
(14,555)
(9,473)
Balance
Cash
9,310
4,120
Long term investments
Excess cash
9,310
4,120
Stockholders' equity
(13,329)
(8,308)
Invested Capital
23,979
11,854
ROIC
ROCE
EV
Common stock shares outstanding
3,919
3,336
Price
90.00
131.96%
38.80
-25.67%
Market cap
352,721
172.50%
129,440
-21.59%
EV
343,684
127,115
EBITDA
(13,872)
(9,144)
EV/EBITDA
Interest
34
32
Interest/NOPBT